Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux have received a boost with the Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.
Merck KGAA says it will work to make Erbitux (cetuximab) available for patients in China as a first-line treatment for metastatic colorectal cancer (mCRC) as soon as possible. But it seems that the real benefit for the German company of any label expansion will be in helping build its brand presence in China rather than in absolute sales.
Erbitux was first approved in China for use in combination with irinotecan or as a single agent for mCRC refractory...
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
